90results about How to "Low serum levels" patented technology

Methods and compositions for preserving the function of insulin-producing cells and to furthering the lifespan of insulin-producing cells in non-insulin dependent patients with insulin-related disorders are provided.

The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.

Disclosed is a novel food product characterized by a low glucose or glucose free content, a balanced functional fat content, and a proactive agent aimed for the diabetic and diabetic-prone populations. The food product of the invention is a functional food which may be used clinically to lower the lipid level in people suffering from an imbalanced lipid profile and which may progress towards diabetes complications and coronary vascular disorders. In particular embodiments the proactive agent can be any of a naturally occurring lipid, a synthetic or mimetic lipid which is not digestible by humans and interferes with body weight gain/loss, plant extracts and substances derived therefrom, antioxidants, animal-derived substances, minerals and pharmaceuticals, and any mixture thereof.

Statin therapy has revolutionized the treatment of cardiovascular disease, but not all patients can take the appropriate level of statins because of their side effects. The present invention provides compositions that provide potent cholesterol lowering while minimizing the damaging side effects to liver, muscles, and neurons, and has the added benefit of reducing chronic systemic inflammation, which is an independent determinant of cardiovascular disease and all-cause mortality. The current invention presents pharmaceutical compositions for reducing cholesterol and chronic systemic inflammation comprising therapeutically effective amounts of: at least one lipid-lowering agent chosen from HMG-CoA reductase inhibitors, high-dose controlled-release niacin, red yeast rice, or policosanol; and at least one antiinflammatory natural product chosen from alpha-lipoic acid and corosolic acid. To those in need of such treatment, the current invention also provides safe methods for reducing high serum cholesterol or chronic inflammation, or for simultaneously reducing both cholesterol and chronic inflammation via treatment with therapeutically effective daily doses of pharmaceutical compositions as described herein. The present invention provides mammals with compositions and methods for concurrently reducing cholesterol and inflammation as a prevention or treatment for many age-related diseases and disorders.

The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis.

The present invention provides transformed bone marrow-related cells that are associated with tissue maintenance and/or repair. Further, the invention provides methods for diagnosing and treating diseased tissues using the transformed bone marrow-related cells. The transformed bone marrow-related cells of the present invention are transformed bone marrow-related cells that are introduced with gene-carrying vectors and that are associated with tissue maintenance and/or repair. Moreover, the methods for preparing the transformed bone marrow-related cells of the present invention comprise the step of using gene-carrying vectors to introduce genes to bone marrow-related cells taken from mammals.

Phamaceutical compositions are provided that are useful in treating amyloid protein-related diseases such as Alzheimer's disease. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that downregulates one or more genes related to the amyloid-related disease. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of amyloid protein-related diseases. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl), and the amyloid protein-related disease is Alzheimer's disease. In a preferred embodiment, the downregulated genes are genes related to inflammation or oxidative stress.

The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.

A method of reducing the serum level in a mammal of any one more cholesterol, low density lipoprotein (LDL) cholesterol relative to high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, apolipoprotein B, and triglycerides by the ingestion of a composition containing β-casein A². A dietary supplement formed by the addition of β-casein to a food or drink for human consumption where the β-casein is comprised of at least 95% β-casein A², preferably solely β-casein A².

Novel methods and drug products for treating inflammatory joint diseases such as rheumatoid arthritis and associated arthritides are disclosed. The methods and products employ various serum markers of bone and cartilage metabolism or destruction, including cartilage oligomer matrix protein (COMP) and Receptor activator of NFB ligand (RANKL), as biomarkers to assess the effect of IL-17A antagonists on joint destruction in inflammatory joint diseases.

The present invention relates to compositions and methods for the use of T cells and more particularly, activated T cells, in the treatment and/or amelioration of diseases associated with a proinflammatory state, such as cachexia, chronic diseases such as chronic renal failure, and hepatitis.

World Health Organization thinks that the rise in triglyceride is a major cause for occurrence of atherosclerosis. The U.S. classical anti-arteriosclerosis drug—atromid-s can reduce TG and VLDL remarkably and inhibit the synthesis and release of TG the effects of the five-plant compound hypolipemic products are better than that of atromid-s. They are made under delicate and strictly controlled conditions by absorbing, eluting, isolating and purifying the five-plant components with supercritical CO₂ extraction and WLD resin absorption techniques and quantitative analysis by fingerprinting through high performance liquid chromatography to ensure the uniformity and stability of product quality. The results of experiments on pharmacological activity show the compound products have the pharmacological action to inhibit the rise in serum cholesterol in rabbit, enhance LCAT activity and reduce the content of serum cholesterol and triglyceride, clinically They can be used in the treatment of atherosclerosis and obesity.

The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection.

The present invention relates to antibodies (particularly humanized antibodies) against hepatitis B surface antigen (HBsAg), nucleic acid molecules encoding the antibodies, methods for preparing the antibodies, and pharmaceutical compositions containing the antibodies. Furthermore, the invention relates to use of the antibodies and the pharmaceutical compositions. The antibodies and pharmaceuticalcompositions are useful for preventing and/or treating HBV infection or hepatitis B infection and related diseases (such as hepatitis B), for neutralizing the virulence of HBV in a subject (such as ahuman), or for reducing serum levels of HBV DNA and/or HBsAg in the subject.

A pharmaceutical composition comprising an effective amount of a compound of formulas (I-III) and a pharmaceutically acceptable carrier. Methods for treating a hepatitis virus in a patient comprising administering an effective amount of the compound of formulas (I-III) are also presented.

Described are medicaments and methods of treating or preventing metabolic bone diseases, such as Critical Illness Related Metabolic Bone Disease or of critical illness induced Osteopenia secondary to ICU Admission by sufficient autophagy inducing compound to inhibit or suppress critical illness enhanced osteoclastogenesis or increased osteoclast differentiation. The methods include administering of an autophagy activating compound to a mammal to: treat or prevent a bone degenerative disorder; slow bone deterioration; restore lost bone; maintain bone mass and/or bone quality or inhibit bone resorption in particularly by inhibiting or reducing a process by which osteoclasts break down bone and release the minerals resulting in a transfer of calcium from bone fluid to the blood. Also described are methods for administering the autophagy activating compound to treat a bone disorder of hyperresorption of bone and/or enhanced activation of osteoclasts.